Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

However, the control group had a significantly longer follow-up duration (median 46 vs. 33 months, p = 0.021), and calcium/vitamin D supplementation was more frequent in the control group (70% vs. 30%, p = 0.026).

Source: 3.1. Study Population and Baseline Characteristics. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Observational study.

Observational study

Observes exposures and outcomes without assigning the exposure; the subtype is not established here.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

This single-center retrospective observational study was conducted in a tertiary care setting.

Source: Methods.

Patients were included if they had a confirmed diagnosis of osteoporosis, available baseline and follow-up clinical data, and sufficient follow-up to allow assessment of vertebral fracture outcomes and pain progression.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Ibandronate Use in Osteoporotic Vertebral Fractures: A Retrospective Clinical Study Integrated with Exploratory Network Pharmacology and Cross-Cohort Transcriptomic Analysis

Observational study · Biomedicines · 2026

Original publication title

Ibandronate Use in Osteoporotic Vertebral Fractures: A Retrospective Clinical Study Integrated with Exploratory Network Pharmacology and Cross-Cohort Transcriptomic Analysis

Mehmet Albayrak; Ersin Guner; Fatih Ugur; Ibrahim Yilmaz

© 2026 by the authors.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Background:

Ibandronate is a nitrogen-containing bisphosphonate used in osteoporosis; however, its relationship with vertebral-fracture-related outcomes, pain trajectories, and broader inflammatory: skeletal signaling remains incompletely characterized.

Methods:

This retrospective observational study included patients with osteoporosis categorized according to ibandronate exposure. The primary outcome was new vertebral fracture occurrence, and the secondary outcome was change in pain severity assessed using the Visual Analog Scale (VAS). Multivariable regression, sensitivity analyses, and exploratory network-pharmacology, transcriptomic, and molecular docking analyses were performed.

Results:

Forty patients (20 ibandronate, 20 control) were included. Ibandronate use was associated with numerically lower vertebral fracture occurrence, although this did not reach statistical significance in crude or adjusted analyses. Greater pain reduction was observed in unadjusted analyses but was attenuated after multivariable adjustment, and baseline heterogeneity should be considered when interpreting between-group differences. Radiological outcomes did not differ significantly between groups. Exploratory systems-level analyses identified enrichment patterns involving inflammatory signaling, osteoclast differentiation, cytokine-associated pathways, and skeletal regulatory processes; however, these findings should be interpreted as hypothesis-generating and not as evidence of causal biological mechanisms.

Conclusions:

In this exploratory, hypothesis-generating study, ibandronate use was associated with trends toward lower vertebral fracture occurrence and greater unadjusted pain improvement, although these findings were attenuated after adjustment. The combined clinical, transcriptomic, and computational observations are compatible with the possibility that inflammatory and skeletal regulatory pathways may intersect within a broader systems-level framework relevant to vertebral-fracture-related outcomes in osteoporosis. However, these findings should not be interpreted as direct mechanistic evidence of ibandronate-specific molecular activity or clinical efficacy. Larger prospective studies integrating clinical, radiological, and mechanistic approaches are required to clarify the biological and clinical relevance of these observations.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Ibandronate is a nitrogen-containing bisphosphonate used in osteoporosis; however, its relationship with vertebral-fracture-related outcomes, pain trajectories, and broader inflammatory: skeletal signaling remains incompletely characterized.

Source: Background:

Abstract: Results

Forty patients (20 ibandronate, 20 control) were included. Ibandronate use was associated with numerically lower vertebral fracture occurrence, although this did not reach statistical significance in crude or adjusted analyses. Greater pain reduction was observed in unadjusted analyses but was attenuated after multivariable adjustment, and baseline heterogeneity should be considered when interpreting between-group differences. Radiological outcomes did not differ significantly between groups. Exploratory systems-level analyses identified enrichment patterns involving inflammatory signaling, osteoclast differentiation, cytokine-associated pathways, and skeletal regulatory processes; however, these findings should be interpreted as hypothesis-generating and not as evidence of causal biological mechanisms.

Source: Results:

Abstract: Conclusions

In this exploratory, hypothesis-generating study, ibandronate use was associated with trends toward lower vertebral fracture occurrence and greater unadjusted pain improvement, although these findings were attenuated after adjustment. The combined clinical, transcriptomic, and computational observations are compatible with the possibility that inflammatory and skeletal regulatory pathways may intersect within a broader systems-level framework relevant to vertebral-fracture-related outcomes in osteoporosis. However, these findings should not be interpreted as direct mechanistic evidence of ibandronate-specific molecular activity or clinical efficacy. Larger prospective studies integrating clinical, radiological, and mechanistic approaches are required to clarify the biological and clinical relevance of these observations.

Source: Conclusions:
Authors’ abstract

Background:

Ibandronate is a nitrogen-containing bisphosphonate used in osteoporosis; however, its relationship with vertebral-fracture-related outcomes, pain trajectories, and broader inflammatory: skeletal signaling remains incompletely characterized.

Methods:

This retrospective observational study included patients with osteoporosis categorized according to ibandronate exposure. The primary outcome was new vertebral fracture occurrence, and the secondary outcome was change in pain severity assessed using the Visual Analog Scale (VAS). Multivariable regression, sensitivity analyses, and exploratory network-pharmacology, transcriptomic, and molecular docking analyses were performed.

Results:

Forty patients (20 ibandronate, 20 control) were included. Ibandronate use was associated with numerically lower vertebral fracture occurrence, although this did not reach statistical significance in crude or adjusted analyses. Greater pain reduction was observed in unadjusted analyses but was attenuated after multivariable adjustment, and baseline heterogeneity should be considered when interpreting between-group differences. Radiological outcomes did not differ significantly between groups. Exploratory systems-level analyses identified enrichment patterns involving inflammatory signaling, osteoclast differentiation, cytokine-associated pathways, and skeletal regulatory processes; however, these findings should be interpreted as hypothesis-generating and not as evidence of causal biological mechanisms.

Conclusions:

In this exploratory, hypothesis-generating study, ibandronate use was associated with trends toward lower vertebral fracture occurrence and greater unadjusted pain improvement, although these findings were attenuated after adjustment. The combined clinical, transcriptomic, and computational observations are compatible with the possibility that inflammatory and skeletal regulatory pathways may intersect within a broader systems-level framework relevant to vertebral-fracture-related outcomes in osteoporosis. However, these findings should not be interpreted as direct mechanistic evidence of ibandronate-specific molecular activity or clinical efficacy. Larger prospective studies integrating clinical, radiological, and mechanistic approaches are required to clarify the biological and clinical relevance of these observations.

Publication and source details

Original title: Ibandronate Use in Osteoporotic Vertebral Fractures: A Retrospective Clinical Study Integrated with Exploratory Network Pharmacology and Cross-Cohort Transcriptomic Analysis

Mehmet Albayrak; Ersin Guner; Fatih Ugur; Ibrahim Yilmaz

Biomedicines · 2026

* Correspondence: dryilmazi@yahoo.com© 2026 by the authors.2026https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.This research received no external funding.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T22:22:56.631968+00:00

DOI: 10.3390/biomedicines14061315 · PMC13297545